Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
COGENTIX MEDICAL INC (CGNT)
|
Add to portfolio |
|
|
|
| Price: |
$15.11
| | Metrics |
| OS: |
60.9
|
M
| |
-1
|
% ROE
|
| Market cap: |
$920
|
M
| |
-5
|
% ROIC
|
|
Net cash:
|
$26.9
|
M
| |
$0.44
|
per share
|
|
EV:
|
$893
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$2.4
|
M
| |
371.4
|
x EV/EBITDA
|
|
EBIT
|
($760.8)
|
k
| |
|
|
| EPS |
($0.01)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Mar-31-15 | Mar-31-14 | Mar-31-13 | Mar-31-12 | Mar-31-11 | Mar-31-10 |
| Revenues | 56.3 | 51.9 | 26.5 | 24.6 | 22.4 | 16.7 | 10.9 | 10.8 |
| Revenue growth | 8.6% | | 7.9% | 9.6% | 34.4% | 53.1% | 0.8% | -15.8% |
| Cost of goods sold | 18.9 | 16.2 | 3.1 | 3.0 | 3.0 | 11.6 | 8.0 | 9.8 |
| Gross profit | 37.4 | 35.6 | 23.4 | 21.5 | 19.4 | 5.1 | 2.9 | 1.0 |
| Gross margin | 66.5% | 68.7% | 88.2% | 87.6% | 86.6% | 30.5% | 26.8% | 9.4% |
| Selling, general and administrative | | | | | | 12.0 | 10.8 | 10.5 |
| Sales and marketing | 22.9 | 21.3 | 20.2 | 18.1 | 15.2 | | | |
| Research and development | 4.7 | 4.7 | 2.9 | 2.2 | 2.4 | 3.2 | 3.5 | 3.3 |
| General and administrative | 8.3 | 6.8 | 8.0 | 6.5 | 4.2 | | | |
| EBITA | 1.6 | 0.6 | -7.6 | -5.3 | -2.4 | -10.1 | -11.4 | -12.8 |
| EBITA margin | 2.9% | 1.1% | -28.7% | -21.4% | -10.9% | -60.6% | -104.2% | -118.1% |
| Amortization of intangibles | 2.4 | 2.4 | 0.0 | 0.0 | 0.9 | | | |
| EBIT | -0.8 | -1.8 | -7.6 | -5.3 | -3.3 | -10.1 | -11.4 | -12.8 |
| EBIT margin | -1.4% | -3.5% | -28.8% | -21.6% | -14.7% | -60.6% | -104.2% | -118.1% |
| Pre-tax income | -0.6 | -22.0 | -7.6 | -5.3 | -3.3 | -11.0 | -11.8 | -12.8 |
| Income taxes | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | -0.4 |
| Tax rate | | | | | | | | 3.0% |
| Net income | -0.9 | -22.1 | -7.7 | -5.4 | -3.3 | -11.0 | -11.8 | -12.4 |
| Net margin | -1.6% | -42.6% | -29.1% | -21.8% | -14.7% | -66.0% | -108.7% | -114.9% |
| |
| Diluted EPS | ($0.01) | ($0.71) | ($0.49) | ($0.35) | ($0.22) | ($0.25) | ($0.31) | ($0.34) |
| Shares outstanding (diluted) | 60.0 | 30.9 | 15.8 | 15.3 | 15.1 | 44.2 | 38.3 | 36.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|